| Official Full Name |
Recombinant Human soluble Tumor Necrosis Factor Receptor Type II/TNFRSF1B (rHusTNFRII/TNFRSF1B) |
| Squence |
 |
| Amino Acid Sequence |
MPAQVAFTPY APEPGSTCRL REYYDQTAQM CCSKCSPGQH AKVFCTKTSD TVCDSCEDST YTQLWNWVPE CLSCGSRCSS DQVETQACTR EQNRICTCRP GWYCALSKQE GCRLCAPLRK CRPGFGVARP GTETSDVVCK PCAPGTFSNT TSSTDICRPH QICNVVAIPG NASMDAVCTS TSPT |
| Synonyms |
|
| Accession Number |
P20333 |
| GeneID |
7133 |
| Summary |
|
| Source |
|
| Molecular Weight |
Approximately 20.0 kDa, a single non-glycosylated polypeptide chain containing 184 amino acids. |
| Biological Activity |
Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit the TNF-alpha mediated cytotoxicity in the L-929 cells is less than 0.2 ug/ml, corresponding to a specific activity of > 5000 IU/mg in the presence of 0.25 ng/mL of rHuTNF-alpha. |
| Appearance |
Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation |
Lyophilized from a 0.2 um filtered solution in PBS, pH 7.4. |
| Endotoxin |
Less than 0.1 EU/ug of rHusTNF RII/TNFRSF1B as determined by LAL method. |
| Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution. |
| References |
|
| SDS-PAGE |
 |
| Safety Data Sheet (SDS) Download |
Click to download |
| Technical Data Sheet (TDS) Download |
Click to download |
